
Best Of 2025: This Pharma Company Is Betting Big On A Chinese Ozempic Rival
2/1/2026
0:00
5:11
Kailera jumped the weight loss miracle-drug line by licensing four clinical-stage obesity therapies from China, which is quickly emerging as a powerhouse pharmaceutical R&D center. After all, why spend millions trying to develop novel medications in the U.S. when Chinese firms have probably already done it for you?
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Altri episodi di "Forbes Daily Briefing"



Non perdere nemmeno un episodio di “Forbes Daily Briefing”. Iscriviti all'app gratuita GetPodcast.







